NOXXON renegotiates ODIRNANE BSA financing agreement to remove unilateral option for investor to subscribe for tranches and to cancel existing warrants
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), the “Company”, a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it has renegotiated and signed an amendment to its…